Long-Term Outcomes of Biological Therapy in Crohn's Disease Complicated With Internal Fistulizing Disease: BIOSCOPE Study From GETECCU.

Manuel Barreiro-de Acosta,Agnès Fernández-Clotet,Francisco Mesonero,Francisco Javier García-Alonso,María José Casanova,Margarita Fernández-de la Varga,Fiorella Cañete,Luisa de Castro,Ana Gutiérrez,Beatriz Sicilia,Victoria Cano,Olga Merino,Ruth de Francisco,Irene González-Partida,Gerard Surís,Leyanira Torrealba,Rocío Ferreiro-Iglesias,Beatriz Castro,Lucía Márquez,Ana Sobrino,Ainara Elorza,Xavier Calvet,Pilar Varela,Raquel Vicente,Luis Bujanda,Laura Lario,Noemí Manceñido,Mariana F García-Sepulcre,Eva Iglesias,Cristina Rodríguez,Marta Piqueras,Juan Ángel Ferrer Rosique,Alfredo J Lucendo,Olga Benítez,Melody García,David Olivares,Carlos González-Muñoza,Beatriz López-Cauce,Victor Jair Morales Alvarado,Katerina Spicakova,Alicia Brotons,Fernando Bermejo,Pedro Almela,Nahia Ispízua,Pau Gilabert,Carlos Tardillo,Fernando Muñoz,Pablo Navarro, Rosa Eva Madrigal Domínguez,Pau Sendra,Esther Hinojosa,Empar Sáinz,María Dolores Martín-Arranz,Daniel Carpio,Elena Ricart,Berta Caballol,Laura Núñez,Jesús Barrio,Javier P Gisbert,Marisa Iborra,Margalida Calafat,Vicent Hernández,Roser Muñoz Pérez,José Luis Cabriada,Eugeni Domènech,Iago Rodríguez-Lago

JOURNAL OF CROHNS & COLITIS（2023）

引用 2|浏览8

暂无评分

摘要

Biologic therapy is beneficial in approximately three-quarters of patients with fistulizing CD, achieving fistula closure in 24%. However, around one-third still undergo surgery due to refractory disease. Some patient- and lesion-related factors can identify patients who will obtain more benefit from these drugs.

查看译文

关键词

Crohn's disease, fistula, biologic therapy, surgery

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要